Skip to main content
. 2026 Jun 23;17:1722204. doi: 10.3389/fimmu.2026.1722204

Figure 1.

Flowchart graphic outlining a clinical trial for a treatment regimen in patients with newly diagnosed MGRS. The left branch details trial design: patients receive induction with reduced-dose daratumumab, bortezomib, and dexamethasone for six cycles, followed by transplant eligibility evaluation. Both transplant-ineligible and eligible patients are expected to receive maintenance daratumumab for twelve cycles, with follow-up to endpoint. The right branch shows eligibility assessment, screening of twelve patients, exclusion of two, enrollment of ten, and discontinuation by three. Seven patients completed DVd-lite and are alive, and the final intent-to-treat population is ten.

The trial design (left panel) and flow chart of the study (right panel). aThere were six cycles of induction therapy. bDara dose escalation was optional for patients failing achieving a partial response (PR) after one cycle or a very good partial response (VGPR) after three cycles. cAfter 4–6 cycles of treatment, autologous stem cell transplantation (ASCT) consolidation therapy could be selected. dMaintenance therapy was initially planned for 12 cycles, but the maintenance therapy duration among enrolled patients varied due to differences in treatment compliance and funding availability. Abbreviations: Dara, Daratumumab; IV, intravenously; SC, subcutaneously; HDT, high-dose therapy; ASCT, autologous stem cell transplantation; ITT population: intention-to-treat population.